Aurobindo Pharma Announces Voluntary Recall, Adding to Valsartan Concerns

Yet another company has is recalling for blood pressure medication concerns.  Aurobindo Pharma USA Inc has announced a voluntary recall over 80 lots of its valsartan tablets that are suspected to contain a chemical that has been classified as a possible human carcinogen.  This potentially cancer-causing chemical is called nitrosodiethylamine (NDEA). 

The lots include Amodipine Valsartan Tablets, Valsartan HCTZ Tablets, and Valsartan Tablets medications. 

Aurobindo Pharma released their announcement on New Year’s Eve, certainly indicating the urgency of the recall, even though the company has not received any complaints or reports over adverse effects in relation to the drugs. 

As with any other medication recall, patients who have been prescribed these medications should definitely contact their pharmacist or physician to determine an appropriate pharmaceutical alternative. At the same time, medical professionals attest patients should not stop using the medication until they are able to find said appropriate pharmaceutical alternative.  Indeed, it is commonly advised that stopping medication before it has been prescribed to do so and before you find a suitable substitute could have dangerous repercussions.  

Also, the company provides that consumers can contact them via phone at 1.866.850.2876 or via email at [email protected].  Health officials advise that the product can be identified by checking the bottles to confirm the product name and manufacturer details as well as the batch or lot number. 

You may recall that the United States Food and Drug Administration announced, in August, their plan to expand its existing recall of valsartan because they found the product may contain this potentially dangerous impurity.  You might also recall, then, that in November, Teva Pharmaceuticals announced voluntary recalls of two of its drugs over the very same concerns.  Mylan Pharmaceuticals was aso among the group who issued voluntary recalls, this time over their Amlodipine and Valsartan products. Finally, Torrent Pharmaceuticals also issued a voluntary recall of just two lots of Losartan potassium tablets over similar issues regarding traces of the NDEA chemical. 

Also, as a reminder, the FDA has described N-nitrosodiethylamine (NDEA) as a “substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probably human carcinogen.”

Latest News